Company intelligence

PSNL

Personalis, Inc. · NASDAQ · Healthcare

Price$16.21-0.73% · −$0.12

Market cap1.73BEquity value

P / E-14.9Trailing ratio

Volume1.41MLatest session

Market data

PSNL price chart

TradingView

Related signals

1 min delayed

Browse public PSNL signals with their source context and measured market impact. Open any signal for its permanent analysis page.

PSNLJul 20, 2026-14.72% since signal

Tempus AI to acquire Personalis for about $1.5B, expanding oncology portfolio

Tempus AI agreed to acquire Personalis for about $1.5 billion, integrating PSNL into its oncology-focused, AI-enabled precision medicine strategy. The deal signals a strategic premium for PSNL and could catalyze near-term re-rating as Tempus expands its cancer-testing capabilities. Regulatory approvals and financing structure will determine closing timing and eventual impact on PSNL's valuation.

View signal analysis

PSNLMay 20, 2026+8.62% since signal

Medicare Expands Coverage for Personalis' NeXT Personal Breast Cancer Test

The recent expansion of Medicare coverage for Personalis' NeXT Personal test will enable broader usage for active monitoring of breast cancer patients undergoing neoadjuvant therapy. This positive regulatory milestone is expected to enhance physician adoption and ultimately drive revenue growth for the company.

View signal analysis

PSNLAug 6, 2025-18.88% since signal

Super Micro Computer Posts Downbeat Q4 Results, Joins Personalis, Snap And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

Personalis, Inc. reported a significant revenue miss in Q2. PSNL shares declined by 26.1% in pre-market trading. The company also cut its FY25 sales guidance. Weak financial performance affected market sentiment toward PSNL. Overall pre-market trends show many stocks declining.

View signal analysis

Research